Status:
TERMINATED
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
Lead Sponsor:
NeurogesX
Conditions:
Herpes Zoster
Neuralgia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before e...
Eligibility Criteria
Inclusion
- Key Eligibility Criteria:
- Must have completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114.
- Demonstrated adherence to protocol requirements during Study C111, and willing and able to comply with protocol requirements for the duration of the study participation.
- Must not have had any serious adverse experience since enrollment in Study C111, whether or not considered to be study drug-related.
- Must have intact skin at the treatment area.
- Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks).
- Must not use topical pain medications on painful areas.
- Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed.
- No history or current problem with substance abuse.
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00089557
Last Update
June 24 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.